Patents Assigned to Merck Sharp
  • MODULATION OF PILR RECEPTORS TO TREAT SEPSIS
    Publication number: 20130323239
    Abstract: The present invention provides methods of using agonists and antagonists of PILR? and PILR?, respectively, to treat immune mediated sepsis. Also provided are methods of prophylactically treating with agonists and antagonists of PILR? and PILR?, respectively, to prevent the development of sepsis.
    Type: Application
    Filed: August 8, 2013
    Publication date: December 5, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Antara Banerjee, Paul G. Heyworth
  • CATHEPSIN CYSTEINE PROTEASE INHIBITORS
    Publication number: 20130324610
    Abstract: This invention relates to deuterated compounds which are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: February 9, 2012
    Publication date: December 5, 2013
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Kelem Kassahun, Christne Fandozzi, Donald R. Gauthier, Lisa A. Shipley
  • PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST
    Publication number: 20130324728
    Abstract: The present invention is directed to processes for preparing a pyridyl piperidine compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 24, 2011
    Publication date: December 5, 2013
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Yun Shao Feng, Anthony Moses, Yong-Li Zhong
  • Anti-PCSK9 and methods for treating lipid and cholesterol disorders
    Patent number: 8598320
    Abstract: The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: December 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph A. Hedrick, Frederick James Monsma, Jr., Tatyana Churakova, Diane Hollenbaugh
  • Process for preparing a 2-alkynyl substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
    Patent number: 8598343
    Abstract: A process for preparing 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine, intermediates useful in that process, and processes for preparing said intermediates are disclosed.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: December 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shen-Chun Kuo, Yonggang Chen, Jeffrey M. Eckert, William W. Leong, Nanfei Zou, Gabriel C. Kuklis
  • Fused tricyclic compounds for the treatment of inflammatory disorders
    Patent number: 8598158
    Abstract: The present invention relates to certain lactam ring-containing compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein D, E, X1, R1, R2, R3, R4, R9, and R10 are as herein described. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, and chronic obstructive pulmonary disorder.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: December 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Dong Xiao, Anandan Palani, Robert G. Aslanian, Sylvia Degrado, Xianhai Huang, Wei Zhou, Michael Sofolarides, Xiao Chen
  • Method of treatment using fatty acid synthesis inhibitors
    Patent number: 8598153
    Abstract: The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: December 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sheo B. Singh, Michael R. Tota, Jun Wang
  • P2X3, receptor antagonists for treatment of pain
    Patent number: 8598209
    Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: December 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher S. Burgey, Zhengwu J. Deng, Diem N. Nguyen, Daniel V. Paone, Anthony W. Shaw, Anthony Ginnetti
  • MAMMALIAN CYTOKINE; RELATED REAGENTS
    Publication number: 20130316354
    Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: July 22, 2013
    Publication date: November 28, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventor: J. Fernando Bazan
  • Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
    Patent number: 8591943
    Abstract: The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: November 26, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yongqi Deng, Binyuan Sun, Hongbo Zeng, Matthew Richards, Gerald W. Shipps, Jr., Cliff C. Cheng, Yinyan Zhao, Andrew McRiner, Zhaoyang Meng, Yang Nan, Mehul F. Patel, Iwona E. Wrona, Panduranga Adulla Reddy, Brian M. Eklov, Shuyi Tang, Duan Liu, Amit K. Mandal, Lianyun Zhao, M. Arshad Siddiqui
  • Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
    Patent number: 8592425
    Abstract: The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: November 26, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Mark T. Bilodeau, Jongwon Lim, Alan Northrup, Matthew G. Stanton, Brandon M. Taoka
  • Isonicotinamide orexin receptor antagonists
    Patent number: 8592457
    Abstract: The present invention is directed to isonicotinamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: November 26, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Mamio Christa Mattern, Swati P. Mercer, Thomas S. Reger, Anthony J. Roecker
  • Therapeutic compounds
    Patent number: 8591878
    Abstract: A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, B, Z, M, W and n are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: November 26, 2013
    Assignees: Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti Spa
    Inventors: John A. McCauley, Nigel J. Liverton, Steven Harper, Charles J. McIntyre, Michael T. Rudd
  • Cycloalkyl-fused tetrahydroquinolines as CRTHreceptor modulators
    Patent number: 8592383
    Abstract: The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R1, R2, R7, R8, R8a, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: November 26, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xianhai Huang, Jason Brubaker, Scott L. Peterson, John W. Butcher, Joshua T. Close, Michelle Martinez, Rachel Nicola MacCoss, Joon O. Jung, Phieng Siliphaivanh, Hongjun Zhang, Robert G. Aslanian, Purakkattle Johny Biju, Li Dong, Ying Huang, Kevin D. McCormick, Anandan Palani, Ning Shao, Wei Zhou
  • Process for the synthesis of 3-amino-3-cyclobuthylmethyl-2-hydroxypropionamide or salts thereof
    Patent number: 8586765
    Abstract: A process for preparing 3-amino-3-cyclobutylmethyl-2-hydroxypropionamide of the Formula I: or a salt thereof involves providing a compound of the Formula VI described herein in a solution comprising predominately dimethylsulfoxide (DMSO) and converting this compound directly to the compound of the Formula VIII described herein without working up or isolating the intermediate compound of the Formula VII described herein.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: November 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shuan Dong, Jeonghan Park, Eugene John Vater
  • IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors
    Patent number: 8586543
    Abstract: The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: November 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ahmed A. Samatar, Brian Long, Priya Dayananth, Diane Levitan, Marsha Smith
  • Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
    Patent number: 8586576
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: November 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Kartik M. Keertikar
  • Use of IL-23 antagonists for treatment of infection
    Patent number: 8586035
    Abstract: Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: November 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Manfred Kopf, Luigina Romani, Robert A. Kastelein, Alissa A. Chackerian
  • Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
    Patent number: 8580807
    Abstract: The present invention relates to Bicyclic Piperidine and piperazine Derivatives, compositions comprising a Bicyclic Piperidine and piperazine Derivative, and methods of using the Bicyclic Piperidine and piperazine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: November 12, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig D. Boyle, Claire M. Lankin, Unmesh G. Shah, William J. Greenlee, Samuel Chackalamannil
  • Gamma secretase modulators
    Patent number: 8580956
    Abstract: In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: November 12, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Zhaoning Zhu, William J. Greenlee, Zhong-Yue Sun, Gioconda Gallo, Ruo Xu, Xianhai Huang, Xiaohong Zhu